Déjà vu all over again: a recurrent flaw in anticoagulant study design

Keyphrases

• Anticoagulants 100%
• Abnormal Uterine Bleeding 100%
• Direct Oral Anticoagulants 66%
• Randomized Controlled Trial 33%
• Bleeding 33%
• Female Patients 33%
• Male Patients 33%
• All Ages 33%
• Warfarin 33%
• Anticoagulation 33%
• Fibrinolysis 33%
• Uterine Bleeding 33%
• Postmarketing 33%
• New Anticoagulants 33%
• Rivaroxaban 33%
• FXI Deficiency 33%
• Anticoagulation Agents 33%
• Registry Trial 33%
• FXI Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Menorrhagia 100%
• Direct Oral Anticoagulant 66%
• Randomized Controlled Trial 33%
• Bleeding 33%
• Warfarin 33%
• Uterus Bleeding 33%
• Rivaroxaban 33%
• F Factor 33%

Neuroscience

• Antithrombotic 100%
• Anticoagulant 100%
• Randomized Controlled Trial 25%
• Warfarin 25%
• Rivaroxaban 25%
• F Factor 25%